Mesoblast (MESO) to Release Quarterly Earnings on Wednesday

Key Points

• Mesoblast (NASDAQ:MESO) is set to announce its H2 2025 earnings on August 27th, with analysts predicting a loss of $0.20 per share and revenue of $7.481 million.
• Hedge funds have been active in acquiring shares of Mesoblast, with recent positions taken by Raymond James Financial, Creative Planning, and Goldman Sachs.
• Analyst sentiment on Mesoblast varies, with a consensus rating of "Buy" and an average target price of $18.00, despite recent downgrades from Jefferies Financial Group.

Mesoblast (NASDAQ:MESO - Get Free Report) is expected to be posting its H2 2025 results before the market opens on Wednesday, August 27th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $7.4810 million for the quarter. Parties may visit the the company's upcoming H2 2025 earningresults page for the latest details on the call scheduled for Wednesday, September 10, 2025 at 6:00 PM ET.

Mesoblast Price Performance

MESO traded up $0.64 on Friday, hitting $15.81. 162,232 shares of the company's stock were exchanged, compared to its average volume of 148,563. The company has a debt-to-equity ratio of 0.22, a current ratio of 0.96 and a quick ratio of 0.63. The stock has a fifty day moving average of $13.38 and a two-hundred day moving average of $13.02. Mesoblast has a twelve month low of $6.00 and a twelve month high of $22.00.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on MESO shares. Jefferies Financial Group cut Mesoblast from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Canaccord Genuity Group raised Mesoblast to a "strong-buy" rating in a research note on Tuesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $18.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MESO. Raymond James Financial Inc. acquired a new position in Mesoblast in the second quarter worth approximately $86,000. Creative Planning bought a new stake in shares of Mesoblast during the 2nd quarter worth $141,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Mesoblast during the 1st quarter worth $3,209,000. Institutional investors own 1.43% of the company's stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.